血清DKK1、β2-微球蛋白水平与多发性骨髓瘤患病程度的相关性*

doi:10.3969/j.issn.1671-2587.2019.06.002

临床输血与检验 ›› 2019, Vol. 21 ›› Issue (6): 564-567.DOI: 10.3969/j.issn.1671-2587.2019.06.002

血清DKK1、β2-微球蛋白水平与多发性骨髓瘤患病程度的相关性^*

冶薇, 程虹, 封敏

830011 乌鲁木齐,新疆医科大学附属肿瘤医院检验科

收稿日期:2018-03-01 出版日期:2019-12-20 发布日期:2019-12-25
通讯作者: 封敏,女,副主任医师,硕士,主要从事临床实验室诊断,（E-mail）326662913@qq.com。
作者简介:冶薇（1981-）,女,新疆人,副主任技师,学士,主要从事临床生物化学诊断工作,（Tel）13565866456。
基金资助:
*本课题受新疆维吾尔自治区自然科学基金（No.2016D01C371）资助

Analysis of Association of Serum Levels of DKK1 and β2-microglobulin with the Progress of Multiple Myeloma Disease

YE Wei, CHENG Hong, FENG Min

Tumor Hospital Affiliated to Xinjiang Medical University 830001

Received:2018-03-01 Online:2019-12-20 Published:2019-12-25

摘要/Abstract

摘要： 目的探讨血清DKK1、β2-微球蛋白水平与多发性骨髓瘤患病程度的相关性。方法选取66例多发性骨髓瘤患者作为研究组,同时选取66例健康体检者作为对照组,分别测定两组患者的血清Wnt通路抑制因子 Dickkopf-1（ DKK1）、β2-微球蛋白水平,分析其与多发性骨髓瘤疾病发病程度的相关性。结果 ①研究组患者的血清DKK1、β2-微球蛋白水平均高于对照组,差异均有统计学意义（P均<0.05）。②不同骨髓瘤期患者血清DKK1、β2-微球蛋白水平的差异均有统计学意义（P均<0.05）;经两两比较,II期、III期血清DKK1、β2-微球蛋白水平均高于I期（P均<0.05）,III期血清DKK1、β2-微球蛋白水平均高于II期（P均<0.05）。③不同病期的血清DKK1、β2-微球蛋白水平的差异有统计学意义（P均<0.05）;经两两比较,肾功能不全期患者血清DKK1、β2-微球蛋白水平均高于其他病期（P均<0.05）,初发期及复发期患者血清DKK1、β2-微球蛋白水平均高于临床缓解期（P均<0.05）。结论血清DKK1、β2-微球蛋白水平与多发性骨髓瘤疾病严重程度呈正相关,检测二者可有效评估患者的病情。

关键词: 多发性骨髓瘤, 血清DKK1, β2-微球蛋白, 相关性

Abstract: Objective To investigate the correlation between serum levels of DKK1 and β2-microglobulin and the multiple myeloma disease progress. Methods Sixty-six patients with multiple myeloma were selected as study group,and sixty-six healthy subjects were selected as control group. The serum levels of Wnt pathway inhibitor Dickkopf-1 （DKK1） and beta2-microglobulin were measured,and their associations with the incidence of multiple myeloma were analyzed. Results ① The serum levels of DKK1 and β2-microglobulin in the study group were significantly higher than those in the control group （P<0.05）. ② The differences of serum DKK1 and β2-microglobulin in different myeloma patients were statistically significant （P<0.05）; After multiple comparison,the serum levels of DKK1 and β2-microglobulin in stage II and III were all higher than those in stage I （P<0.05）,and the levels of DKK1 and β2-microglobulin in stage III were all higher than those in stage II （P<0.05）. ③The difference of serum DKK1 and β2-microglobulin in different stages was statistically significant （P <0.05）; After multiple comparison,the serum levels of DKK1 and β2-microglobulin in patients in renal insufficiency stage were higher than those in other periods （P<0.05）. Serum DKK1 and β2-microglobulin levels in patients in early stage and recurrence stage were higher than those in clinical remission stage （P<0.05）. Conclusion Serum DKK1 and β2-microglobulin levels are positively correlated to the severity of multiple myeloma. The detection of the two markscan effectively evaluate the patient's condition

Key words: Multiple myeloma, Serum DKK1, β2-microglobulin, Correlation

中图分类号:

冶薇, 程虹, 封敏. 血清DKK1、β2-微球蛋白水平与多发性骨髓瘤患病程度的相关性^*[J]. 临床输血与检验, 2019, 21(6): 564-567.

YE Wei, CHENG Hong, FENG Min. Analysis of Association of Serum Levels of DKK1 and β2-microglobulin with the Progress of Multiple Myeloma Disease[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 564-567.

参考文献

1 Wei G,Wang L,Yang H,et al. Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma:[J]. Exp Hematol Oncol,2017,6(1):16.
2 Bosseboeuf A,Feron D,Tallet A,et al. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens[J]. Jci Insight,2017,2(19) pii:95367.
3 陈双,张正昊,张敏,等. 多发性骨髓瘤患者骨髓上清液和血清DKK1表达水平及其临床意义[J]. 中华全科医学,2017,15(9):1472-1474.
4 Chen R,Zhang X,Gao C,et al. Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen:a single Chinese center retrospective study[J]. Cancer Manag Res,2017,9:373-380.
5 秦小琪,徐燕,安刚,等. 肾功能对β2微球蛋白水平作为多发性骨髓瘤国际分期系统预后因素的影响——单中心666例临床分析[J]. 中华血液学杂志,2015,36(5):393-397.
6 Scudia V,Petroba P,Pika T,et al. Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma[J]. Cas Lek Cesk,2015,154(4):181-188.
7 黄亚丽,杨丽萍,薛重重,等. 多发性骨髓瘤患者血清β2-微球蛋白及炎性细胞因子表达的意义[J]. 检验医学,2016,(b11):142-143.
8 Feng X,Deng S,An G,et al. Detection of serum DKK1 in multiple myeloma and myeloma bone disease[J]. 中华血液学杂志,2015,36(8):682.
9 冯晓燕,邓书会,安刚,等. 血清DKK1检测在多发性骨髓瘤及其骨病中的应用[J]. 中华血液学杂志,2015,36(8):682-685.
10 Lu C,Meng S,Jin Y,et al. A novel multi‐epitope vaccine from MMSA‐1 and DKK1 for multiple myeloma immunotherapy[J]. Br J Haematol,2017,178(3):413-426.
11 李强,谢翔,赵洪国. 多发性骨髓瘤患者血清 Dickkopf-1水平变化及意义[J]. 山东医药,2015,(22):72-73.
12 Wang Y,Yee A J,Sirard C,et al. Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma.[J]. Blood Cancer J,2017,7(10):e615.
13 王萍,王冲,任晓艳,等. 血清β-2微球蛋白、乳酸脱氢酶在多发性骨髓瘤诊治中的临床意义分析[J]. 医学综述,2014,20(15):2849-2850.
14 段丽娟,李超,杨如玉,等. 多发性骨髓瘤患者血清β2-微球蛋白、TNF-α、CRP及IL-6水平检测[J]. 中国实验血液学杂志,2015,23(5):1362-1365.
15 Fan L,Hong J,Huang H,et al. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma[J]. Med Sci Monit,2017,23:2636-2643.
16 杜朝阳,杨如玉,李超,等.多发性骨髓瘤患者Th17细胞及IL-17水平与患者发病的相关性分析[J].中国实验血液学杂志,2017,25(1):147-150.

[1]	楚海亮, 邢名泉, 葛洪峰. VCD方案联合乌苯美司治疗多发性骨髓瘤疗效及患者预后影响因素分析[J]. 临床输血与检验, 2021, 23(2): 216-221.
[2]	李伟超, 程道胜. CD38单抗治疗多发性骨髓瘤的配血策略[J]. 临床输血与检验, 2020, 22(6): 624-626.
[3]	何雯, 毕良学, 王宁玲. 支气管哮喘患儿白介素、TNF-α与肺功能及免疫功能的关系研究[J]. 临床输血与检验, 2020, 22(6): 638-642.
[4]	强萍, 薛磊, 汪敏, 许汉英, 刘欣, 朱薇波, 杨林, 王兴兵. 成功救治2例CAR-T细胞治疗后伴严重细胞因子风暴和相关性脑病伴文献复习[J]. 临床输血与检验, 2020, 22(4): 413-419.
[5]	吕晓华. 异常蛋白凝集干扰交叉配血提示确诊1例多发性骨髓瘤[J]. 临床输血与检验, 2020, 22(4): 443-445.
[6]	刘雯雯, 袁丁. 维持性血液透析患者同型半胱氨酸变化及其相关因素分析[J]. 临床输血与检验, 2020, 22(3): 312-315.
[7]	聂丽容, 李庆华, 梁亮, 何红华, 马境志. 硼替佐米联合化疗对多发性骨髓瘤的治疗效果及对VEGF、IL-6、IL-17的影响[J]. 临床输血与检验, 2020, 22(2): 211-214.
[8]	王贵强, 林新梅, 冯均建, 张莉, 卫茂华. 血清KL-6在输血相关性急性肺损伤中应用价值研究[J]. 临床输血与检验, 2019, 21(5): 449-453.
[9]	张丽, 张毓, 孙国栋. 酶免抗-HCV阳性标本中NAT法及胶体金法检测相关性分析[J]. 临床输血与检验, 2019, 21(4): 390-392.
[10]	杨浩, 许军生, 曾湖, 何海权, 冯亦伟. 凝血指标和癌胚抗原表达水平与小细胞肺癌患者生存关系的研究[J]. 临床输血与检验, 2019, 21(4): 417-420.
[11]	陈劲松, 王丽娜. 老年SAP患者外周血T淋巴细胞亚群、血清PCT及hs-CRP水平变化的临床探析^*[J]. 临床输血与检验, 2019, 21(2): 187-190.
[12]	曹伟, 王冰莹, 曹颖, 杨勇, 贾延伟, 杜鸿. 多发性骨髓瘤M蛋白Ig类型改变的探讨^*[J]. 临床输血与检验, 2019, 21(1): 65-67.
[13]	未万东. 肿瘤标志物Cyfra21-1、NSE、CEA、CA125与肺癌骨转移的相关性^*[J]. 临床输血与检验, 2018, 20(5): 514-517.
[14]	孙莹, 刘长春, 郝丽梅, 王佳, 王春玲. RDW、Cys-C与慢性阻塞性肺疾病患者继发肺动脉高压关系的研究[J]. 临床输血与检验, 2018, 20(5): 531-533.
[15]	许婷姝, 李娜. 不良妊娠结局与TORCH感染相关性的临床探析^*[J]. 临床输血与检验, 2018, 20(1): 61-64.

血清DKK1、β2-微球蛋白水平与多发性骨髓瘤患病程度的相关性^*

Analysis of Association of Serum Levels of DKK1 and β2-microglobulin with the Progress of Multiple Myeloma Disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们